These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 30407868

  • 1. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 4. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM, Oh J.
    Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 6. Ozanimod: First Approval.
    Lamb YN.
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [Abstract] [Full Text] [Related]

  • 7. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 8. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 9. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
    Fronza M, Lorefice L, Frau J, Cocco E.
    Drug Des Devel Ther; 2021 Jul; 15():1993-2004. PubMed ID: 34007159
    [Abstract] [Full Text] [Related]

  • 10. Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions.
    Koscielny V.
    Neurodegener Dis Manag; 2018 Jun; 8(3):141-142. PubMed ID: 29943693
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 12. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J.
    J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
    [Abstract] [Full Text] [Related]

  • 13. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A, Whichello C, Le HH, Kern DM, Fernandez GS, Turner V, Das A, Quaife M, Ross AP.
    Patient; 2024 Nov; 17(6):685-696. PubMed ID: 38748388
    [Abstract] [Full Text] [Related]

  • 14. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA.
    Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
    [Abstract] [Full Text] [Related]

  • 15. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R.
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [Abstract] [Full Text] [Related]

  • 16. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S, Li X, Wang J, Wang T, Xu Z, Gao H, Chen G.
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [Abstract] [Full Text] [Related]

  • 17. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.
    Mult Scler; 2022 Oct; 28(12):1944-1962. PubMed ID: 35765217
    [Abstract] [Full Text] [Related]

  • 19. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug 24; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract] [Full Text] [Related]

  • 20. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
    Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, Scott FL.
    PLoS One; 2018 Aug 24; 13(4):e0193236. PubMed ID: 29608575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.